A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

BACKGROUND: Luteinizing hormone-releasing hormone (LH-RH) agonists provide effective adjuvant treatment for premenopausal women with endocrine-responsive breast cancer. Here, we investigated appropriate treatment durations of an LH-RH agonist, leuprorelin. METHODS: We conducted an open-label, random...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiba, Eiichi, Yamashita, Hiroko, Kurebayashi, Junichi, Noguchi, Shinzaburo, Iwase, Hirotaka, Ohashi, Yasuo, Sasai, Kiyofumi, Fujimoto, Tsukasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839052/
https://www.ncbi.nlm.nih.gov/pubmed/25655898
http://dx.doi.org/10.1007/s12282-015-0593-z

Ejemplares similares

Ejemplares similares